Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung cancer

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 246-251

  Lim, Wei Yen ^a   Chuah, Khoon Leong ^b   Eng, Philip ^c   Leong, Swan Swan ^d   Lim, Elaine ^b   Lim, Tow Keang ^e   Ng, Alan ^b   Poh, Wee Teng ^f   Tee, Augustine ^f   Teh, Ming ^e   Salim, Agus ^a   Seow, Adeline ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^e NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^f CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

Aspirin; Epidemiology; Inflammation; Lung cancer; NSAIDs; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; STEROID;

ADULT; AGED; ARTICLE; ASIAN; CANCER RISK; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; ENVIRONMENTAL EXPOSURE; FAMILY HISTORY; FEMALE; FOOD INTAKE; HISTOLOGY; HOSPITAL ADMISSION; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SELF REPORT; SMOKING; TREATMENT DURATION;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASIAN CONTINENTAL ANCESTRY GROUP; ASPIRIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SINGAPORE;

EID: 84863784264     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.03.005     Document Type: Article

References (44)

1. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., van de Putte L.B.A., et al. Cyclooxygenase in biology and disease. FASEB J 1998, 12:106373.
2. Terry M.B., Gammon M.D., Zhang F.F., Tawfik H., Teitelbaum S.L., Britton J.A., et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004, 291:2433-2440.
3. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J Natl Cancer Inst 2002, 94(4):252-266.
4. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., Dubois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107:1183-1188.
5. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., et al. Suppression of intestinal polyposis in APC delta716 knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2). Cell 1996, 87(5):803-809.
6. Flossmann E., Rothwell P.M. British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomized and observational studies. Lancet 2007, 369(9573):1603-1613.
7. Cole B.F., Logan R.F., Halabi S., Benamouzig R., Sandler R.S., Grainge M.J., et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009, 101(4):256-266.
8. Wolff H., Saukkonen K., Antilla S., Karjalainen A., Vainio H., Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998, 58(22):4997-5001.
9. Rioux N., Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 1998, 58:5354-5360.
10. Dannenberg A.J., Lippman S.M., Mann J.R., Subbaramaiah K., Dubois R.N. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005, 23:254-266.
11. Kim Y.M., Park S.Y., Pyo H. Cyclooxygenase-2 (COX-2) negatively regulates expression of Epidermal Growth Factor Receptor and causes resistance to gefitinib in COX-2 overexpressing cancer cells. Mol Cancer Res 2009, 7(8):1367-1377.
12. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancer. J Natl Cancer Inst 2005, 97:339-346.
13. Schreinemachers D.M., Eversin R.B. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 1994, 5:138-146.
14. Harris R.E., Beebe-Donk J., Schuller H.M. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 2002, 9:693-695.
15. Moysich K.B., Menezes R.J., Ronsani A., Swede H., Reid M.E., Cummings K.M., et al. Regular aspirin use and lung cancer risk. BMC Cancer 2002, 2:31.
16. Muscat J.E., Chen S.Q., Richie J.P., Altorki N.K., Citron M., Olson S., et al. Risk of lung carcinoma among users of nonsteroidal anti-inflammatory drugs. Cancer 2003, 97:1732-1736.
17. Hernandez-Diaz S., Rodriguez L.A.G. Nonsteroidal anti-inflammatory drugs and risk of lung cancer. Int J Cancer 2007, 120:1565-1572.
18. Harris R.E., Beebe-Donk J., Alshafie G.A. Reduced risk of human lung cancer by selective cyclooxygenase 2 blockade: results of a case-control study. Int J Biol Sci 2007, 3:328-334.
19. Van Dyke A.L., Cote M.L., Prysak G., Claeys G.B., Wenzlaff A.S., Schwartz A.G. Regular adult aspirin use decreases the risk of non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev 2008, 17:148-157.
20. Slatore C.G., Au D.H., Littman A.J., Satia J.A., White E. Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study. Cancer Epidemiol Biomarkers Prev 2009, 18:1203-1207.
21. Olsen J.H., Friis S., Poulsen A.H., Fryzek J., Harving H., Tjønneland A., et al. Use of NSAIDs smoking and lung cancer risk. Br J Cancer 2008, 98:232-237.
22. Thun M.J., Namboodiri M.M., Calle E.E., Flanders W.D., Heath C.W. Aspirin use and risk of fatal cancer. Cancer Res 1993, 53:1322-1327.
23. Paganini-Hill A., Chao A., Ross R.K., Henderson B.E. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989, 299:1247-1250.
24. Rosenberg L. Nonsteroidal anti-inflammatory drugs and cancer. Prev Med 1995, 24:107-109.
25. Langman M.J., Cheng K.K., Gilman E.A., Lancashire R.J. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000, 320:1642-1646.
26. Akhmedkhanov A., Toniolo P., Zeleniuch-Jacquotte A., Koenig K.L., Shore R.E. Aspirin and lung cancer in women. Br J Cancer 2002, 87:49-53.
27. Friis S., Sørensen H.T., McLaughlin J.K., Johnsen S.P., Blot W.J., Olsen J.H. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003, 88:684-688.
28. Sørensen H.T., Friis S., Nørgård B., Mellemkjaer L., Blot W.J., McLaughlin J.K., et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003, 88:1687-1692.
29. Holick C.N., Michaud D.S., Leitzmann M.F., Willett W.C., Giovannucci E. Aspirin use and lung cancer in men. Br J Cancer 2003, 89:1705-1708.
30. Hayes J.H., Anderson K.E., Folsom A.R. Association between nonsteroidal anti-inflammatory drug use and the incidence of lung cancer in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2006, 15:2226-2231.
31. Feskanich D., Bain C., Chan A.T., Pandeya N., Speizer F.E., Colditz G.A. Aspirin and lung cancer risk in a cohort study of women: dosage, duration and latency. Br J Cancer 2007, 97:1295-1299.
32. Kelly J.P., Coogan P., Strom B.L., Rosenberg L. Lung cancer and regular use of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Pharmacoepidemiol Drug Saf 2007, 17:322-327.
33. Khuder S.A., Herial N.A., Mutgi A.B., Federman D.J. Nonsteroidal anti-inflammatory drug use and lung cancer: a metaanalysis. Chest 2005, 127:748-754.
34. Bosetti C., Gallus S., La Vecchia C. Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 2006, 17:871-888.
35. Peto R., Gray R., Collins R., Wheatley K., Hennekens C., Jamrozik K., et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988, 296:313-316.
36. Lee I., Manson C., Hennekens C. Low-dose aspirin and risk of cancer: the Physicians' Health Study. Am J Epidemiol 1995, 141. [Abstract S281].
37. Cook N.R., Lee I.M., Gaziano J.M., Gordon D., Ridker P.M., Manson J.E., et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005, 294:47-55.
38. Rothwell P.M., Fowkes F.G.R., Belch J.F.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomized trials. Lancet 2010, 10.1016/S0140-6736(10)62110-1.
39. National Registry of Diseases Office, Singapore. Trends in cancer incidence in Singapore 1968-2007. Singapore Cancer Registry Report No. 7, 2010 [accessed 28.01.11]. http://www.nrdo.gov.sg/uploadedFiles/NRDO/Publications/inc_report_v8.pdf.
40. Epidemiology & Disease Control Division. National Health Survey 2004. Ministry of Health, Singapore. 2005 [accessed 28.01.11]. http://www.moh.gov.sg/mohcorp/publicationsreports.aspx?id=2984.
41. Tang L., Lim W.Y., Eng P., Leong S.S., Lim T.K., Ng A.W., et al. Lung cancer in Chinese women: evidence for an interaction between tobacco smoking and exposure to inhalants in the indoor environment. Environ Health Perspect 2010, 118(9):1257-1260.
42. Tamura M., Deb S., Sebastian S., Okamura K., Bulun S.E. Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. Fertil Steril 2004, 81:1351-1356.
43. Wacholder S., McLaughlin J.K., Silverman D.T., Mandel J.S. Selection of controls in case control studies. I. Principles. Am J Epidemiol 1992, 135(9):1019-1028.
44. Koo L.C., Ho J.H.C. Worldwide epidemiological patterns of lung cancer in nonsmokers. Int J Epidemiol 1990, 19:S14-S23. Suppl.